Adding short-course high-dose radiation to standard treatment for people with oligometastatic non-small cell lung cancer
Official title: Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease - An Open Label Randomized Phase III Trial Comparing Up-front Radiation in Oligometastatic Non-small Cell Lung Cancer (NSCLC) and Systemic Treatment With Systemic Treatment Alone
Run by Vastra Gotaland Region · NCT06141070 · Data updated 2026-11-12
This trial will test whether giving focused high-dose radiation to all known tumors along with standard systemic therapy helps people with non-small cell lung cancer who have five or fewer metastases.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 240 (estimated) |
| Sponsor | Vastra Gotaland Region Government |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 6 sites (Gothenburg and 5 other locations) |
| Status | Recruiting |
| Started | December 1, 2023 |
| Main results expected | December 1, 2028 |
| Study ends | December 1, 2028 |
| Registry record updated | April 14, 2026 |
| Trial ID | NCT06141070 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with histologically confirmed NSCLC, stage IV with five or fewer metastases, WHO performance status 0–2, no prior systemic or radiotherapy for metastatic disease, and lesions amenable to SBRT or conventional radiotherapy are ideal candidates.
✕Probably not a fit
Patients with more than five metastases, poor performance status, lesions not suitable for targeted radiotherapy, or who have already received systemic therapy for metastatic NSCLC are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, open-label phase III trial that randomizes patients 2:1 to receive standard first-line systemic therapy with or without additional hypofractionated high-dose radiotherapy to all known lesions. Radiotherapy is planned during the first three months of systemic therapy, preferably using SBRT/SRT/SRS but allowing conventional radiotherapy when needed. Systemic therapy follows local practice (chemotherapy, chemoimmunotherapy, or immunotherapy) with response assessed after three to four cycles and radiologic follow-up every three months. Patients are stratified by performance status, gender, and systemic treatment strategy.
Why it matters
Potential benefit: If successful, adding targeted high-dose radiotherapy could improve local tumor control and extend progression-free and possibly overall survival for patients with limited metastatic NSCLC.
How similar studies have gone: Earlier randomized phase II trials and phase II data in oligometastatic NSCLC and other cancers have suggested progression-free survival benefits from adding local ablative radiotherapy, but phase III confirmation is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Written informed consent obtained from the subject prior to performing any protocol- related procedures, including screening procedures
* Histological or cytological diagnosis of NSCLC
* Stage IV disease with ≤5 metastases (not including primary tumour or mediastinal nodes, N1-N3)
* Patient deemed fit for first line chemoimmunotherapy, immunotherapy or chemotherapy
* Extra-thoracic metastases accessible for stereotactic body radiotherapy (SBRT)
* Thoracic tumour(s) accessible for SBRT or conventional radiotherapy
* Received no prior systemic treatment or radiation therapy for NSCLC (previous adjuvant systemic therapy is allowed)
* Age \> 18 years at time of study entry, no upper age limit
* WHO performance status 0-2
* Adequate normal organ and marrow function Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal subjects.
* Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
Exclusion Criteria:
* • Solitary brain lesion or contralateral lung lesion as the only distant metastasis
* Participation in another clinical study with an investigational product during the last 4 weeks
* Patients with EGFR+, ALK+, ROS1+ disease or any other genetic alteration that would result in a TKI based first line treatment (i.e. first line treatment not being chemoimmuno- or immunotherapy)
* Malignant pleural fluid, or ascites (malignant cells or clinical judgement) or excessive fluid hampering radiation according to protocol
* Leptomeningeal disease
* Pulmonary fibrosis making protocol stipulated treatment hazardous (low grade radiologic findings are allowed as assessed by the investigator)
* Not deemed fit for standard first line systemic therapy
* Second primary residual malignancy. Other malignancy diagnosed and treated \> 2 years ago without relapse and deemed to have a low likelihood of relapse is allowed. (Carcinoma in situ of the cervix or adequately treated basal cell carcinoma of the skin \< 2 years are allowed, as is other low-grade malignancy with low likelihood of becoming metastatic or impact on survival e.g. low-grade prostate cancer not in need of treatment)
* Female subjects who are pregnant or breastfeeding or male or female subjects of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of systemic therapy
* Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
Where it's running
-
Dept of Oncology
Gothenburg, Sweden Recruiting -
Dept of Oncology
Stockholm, Sweden Recruiting -
Dept. of Oncology
Umeå, Sweden Recruiting -
Dept. of Oncology
Uppsala, Sweden Recruiting -
Dept of pulmonary medicine
Linköping, Sweden Not yet recruiting -
Dept of pulmonary medicine
Lund, Sweden Not yet recruiting
Study contacts
- Study coordinator: Andreas Hallqvist
- Email: andreas.hallqvist@vgregion.se
- Phone: +46313427954
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies
This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery
This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.
-
HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC
This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.